Background Diagnosis of significant coronary artery disease (CAD) in at risk patients can be challenging, typically including non-invasive imaging modalities and ultimately the gold standard of coronary angiography. Previous studies suggested that peripheral blood gene expression can reflect the presence of CAD. Objective To validate a previously developed 23-gene expression-based classifier for diagnosis of obstructive CAD in non-diabetic patients. Design Multi-center prospective trial with blood samples drawn prior to coronary angiography. Setting Thirty-nine US centers. Patients An independent validation cohort of 526 non-diabetic patients clinically-indicated for coronary angiography Intervention None. Measurements Receiver-operator characteristics (ROC) analysis of classifier score measured by real-time polymerase chain reaction (RT-PCR), additivity to clinical factors, and reclassification of patient disease likelihood vs disease status defined by quantitative coronary angiography (QCA). Obstructive CAD defined as ≥50% stenosis in ≥1 major coronary artery by QCA. Results The overall ROC curve area (AUC) was 0.70 ±0.02, (p<0.001); the classifier added to clinical variables (Diamond-Forrester method) (AUC 0.72 with classifier vs 0.66 without, p = 0.003). Net reclassification was improved by the classifier over Diamond-Forrester and an expanded clinical model (both p<0.001). At a score threshold corresponding to 20% obstructive CAD likelihood (14.75), the sensitivity and specificity were 85% and 43%, yielding NPV of 83% and PPV 46%, with 33% of patient scores below this threshold. Limitations The study excluded patients with chronic inflammatory disorders, elevated white blood counts or cardiac protein markers, and diabetes. Conclusions This non-invasive whole blood test, based on gene expression and demographics, may be useful for assessment of obstructive CAD in non-diabetic patients without known CAD. Primary Funding Source CardioDx, Inc.
Background-The molecular pathophysiology of coronary artery disease (CAD) includes cytokine release and a localized inflammatory response within the vessel wall. The extent to which CAD and its severity is reflected by gene expression in circulating cells is unknown. Key Words: gene expression Ⅲ coronary disease Ⅲ blood, peripheral Ⅲ atherosclerosis Ⅲ leukocytes Ⅲ polymerase chain reaction Ⅲ stenosis C oronary artery disease (CAD) and sequelae of atherosclerotic disease such as stroke and myocardial infarction are the largest source of morbidity and mortality in the developed world. The risk of developing CAD events over time can be estimated with clinical factors and family history, as in the Framingham Risk Score. 1 For patients with suspicious clinical histories, extant coronary disease may be diagnosed by indirect methods, including nuclear perfusion imaging and computed tomography angiography, but coronary angiography remains the "gold standard." These tests have drawbacks, including radiation exposure, contrast agent allergy, nephrotoxicity, and, in the case of coronary angiography, invasiveness of the procedure. Therefore, the development of a blood test that reliably identified patients with CAD would have diagnostic utility. Methods and Results-From Editorial see p 7 Clinical Perspective see p 38The cellular and molecular basis of atherosclerotic plaque development has a systemic inflammatory component involving primarily monocytes/macrophages and CD4 ϩ T cells. 2,3 Oxidized lipids initiate the process with subsequent responses by endothelial, vascular smooth muscle cells, and circulating cells. Peripheral-blood studies have identified gene expression signatures that are correlated with the presence of systemic inflammatory and immune-mediated disorders, as well as cardiovascular diseases, 4 suggesting that such an approach might be useful for CAD. However, although investigators have identified profiles for atherosclerosis directly from arterial wall samples in murine models and human atheroma samples, 5-9 it is unclear whether such localized processes are detectable or their severity reflected in the peripheral circulation. As a first step, we sought to identify genes for which expression levels distinguished patients with and without significant coronary artery stenosis. We approached this problem by microarray analysis on an angiographically defined patient cohort to identify a set of discriminatory genes. We then replicated these results using real-time polymerase chain reaction (RT-PCR) on 2 addi-
BackgroundAlterations in gene expression in peripheral blood cells have been shown to be sensitive to the presence and extent of coronary artery disease (CAD). A non-invasive blood test that could reliably assess obstructive CAD likelihood would have diagnostic utility.ResultsMicroarray analysis of RNA samples from a 195 patient Duke CATHGEN registry case:control cohort yielded 2,438 genes with significant CAD association (p < 0.05), and identified the clinical/demographic factors with the largest effects on gene expression as age, sex, and diabetic status. RT-PCR analysis of 88 CAD classifier genes confirmed that diabetic status was the largest clinical factor affecting CAD associated gene expression changes. A second microarray cohort analysis limited to non-diabetics from the multi-center PREDICT study (198 patients; 99 case: control pairs matched for age and sex) evaluated gene expression, clinical, and cell population predictors of CAD and yielded 5,935 CAD genes (p < 0.05) with an intersection of 655 genes with the CATHGEN results. Biological pathway (gene ontology and literature) and statistical analyses (hierarchical clustering and logistic regression) were used in combination to select 113 genes for RT-PCR analysis including CAD classifiers, cell-type specific markers, and normalization genes.RT-PCR analysis of these 113 genes in a PREDICT cohort of 640 non-diabetic subject samples was used for algorithm development. Gene expression correlations identified clusters of CAD classifier genes which were reduced to meta-genes using LASSO. The final classifier for assessment of obstructive CAD was derived by Ridge Regression and contained sex-specific age functions and 6 meta-gene terms, comprising 23 genes. This algorithm showed a cross-validated estimated AUC = 0.77 (95% CI 0.73-0.81) in ROC analysis.ConclusionsWe have developed a whole blood classifier based on gene expression, age and sex for the assessment of obstructive CAD in non-diabetic patients from a combination of microarray and RT-PCR data derived from studies of patients clinically indicated for invasive angiography.Clinical trial registration informationPREDICT, Personalized Risk Evaluation and Diagnosis in the Coronary Tree, http://www.clinicaltrials.gov, NCT00500617
Background-Obstructive coronary artery disease diagnosis in symptomatic patients often involves noninvasive testing before invasive coronary angiography. A blood-based gene expression score (GES) was previously validated in nondiabetic patients referred for invasive coronary angiography but not in symptomatic patients referred for myocardial perfusion imaging (MPI). Methods and Results-This prospective, multicenter study obtained peripheral blood samples for GES before MPI in 537 consecutive patients. Patients with abnormal MPI usually underwent invasive coronary angiography; all others had research coronary computed tomographic angiography, with core laboratories defining coronary anatomy. A total of 431 patients completed GES, coronary imaging (invasive coronary angiography or computed tomographic angiography), and MPI. Mean age was 56±10 years (48% women). The prespecified primary end point was GES receiver-operating characteristics analysis to discriminate ≥50% stenosis (15% prevalence by core laboratory analysis). Area under the receiver-operating characteristics curve for GES was 0.79 (95% confidence interval, 0.73-0.84; P<0.001), with sensitivity, specificity, and negative predictive value of 89%, 52%, and 96%, respectively, at a prespecified threshold of ≤15 with 46% of patients below this score. The GES outperformed clinical factors by receiver-operating characteristics and reclassification analysis and showed significant correlation with maximum percent stenosis. Six-month follow-up on 97% of patients showed that 27 of 28 patients with adverse cardiovascular events or revascularization had GES >15. Site and core-laboratory MPI had areas under the curve of 0.59 and 0.63, respectively, significantly less than GES. Conclusions-GES
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.